Montelukast - Warnings and Precautions

5 WARNINGS AND PRECAUTIONS Do not prescribe montelukast sodium to treat an acute asthma attack .

Advise patients to have appropriate rescue medication available .

Inhaled corticosteroid may be reduced gradually.

Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids .

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium .

Neuropsychiatric events have been reported with montelukast sodium.

Instruct patients to be alert for neuropsychiatric events.

Evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur ( 5.4 and 6.2 ).

Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported.

These events have been sometimes associated with the reduction of oral corticosteroid therapy ( 5.5 and 6.2 ).

5.1 Neuropsychiatric Events Serious neuropsychiatric (NP) events have been reported with use of montelukast sodium.

These postmarketing reports have been highly variable and included, but were not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor.

NP events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder.

NP events have been reported mostly during montelukast sodium treatment, but some were reported after montelukast sodium discontinuation.

Animal studies showed that montelukast distributes into the brain in rats [see Clinical Pharmacology ]; however, the mechanisms underlying montelukast sodium-associated NP events are currently not well understood.

Based upon the available data, it is difficult to identify risk factors for or quantify the risk of NP events with montelukast sodium use.

Because of the risk of NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies.

Reserve use of montelukast sodium for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage ].

In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing montelukast sodium.

Discuss the benefits and risks of montelukast sodium use with patients and caregivers when prescribing montelukast sodium.

Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms when taking montelukast sodium.

If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue montelukast sodium and contact a healthcare provider immediately.

In many cases, symptoms resolved after stopping montelukast sodium therapy; however, in some cases symptoms persisted after discontinuation of montelukast sodium.

Therefore, continue to monitor and provide supportive care until symptoms resolve.

Re-evaluate the benefits and risks of restarting treatment with montelukast sodium if such events occur.